This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Objective Pulsed-field ablation (PFA) is a new technology of catheter ablation for atrialfibrillation (AF). This research is to investigate the feasibility of a new strategy (transoesophageal echocardiography-guided pulsed field ablation, TEEP) to guide PFA for AF with no contrast and zero fluoroscopy.
Atrialfibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. What is AtrialFibrillation? Symptoms of AtrialFibrillation Symptoms vary among individuals. Consulting a local cardiologist is crucial for the proper diagnosis and management of AFib.
Ablation index (AI)-guided pulmonary vein isolation (PVI) has enhanced procedural outcomes for atrialfibrillation (AF).1 1 However, patients with persistent AF present higher recurrence rates due to advanced atrial remodeling,2-3 represented by the left atrial low voltage area (LVA), compared to those with paroxysmal AF.
Pulsed field ablation (PFA) is safe for treating patients with common types of atrialfibrillation (AF), according to the largest study of its kind on this new technology, led by the Icahn School of Medicine at Mount Sinai.
Outcomes of ablation with the FARAPULSE PFA System – a nonthermal treatment in which electric fields selectively ablate heart tissue – will be compared to outcomes following use of anti-arrhythmic drug (AAD) therapy, which is commonly prescribed for patients living with persistent AF. The company now anticipates U.S. Circulation.
tim.hodson Thu, 04/24/2025 - 09:52 April 24, 2025 The Heart Rhythm Society (HRS) and the American College of Cardiology (ACC) have released a scientific statement on new guiding principles for Same-Day Discharge (SDD) for patients undergoing intracardiac catheter ablation procedures. Jones, MD, MPH, FACC, FHRS, Co-Chair of the document.
As cryoballoon technology continues to evolve, the introduction of lower-pressure and selectable-size balloons presents new considerations for both safety and efficacy of cryoablation of atrialfibrillation.
Food and Drug Administration (FDA), has granted approval to Boston Scientific for its FARAPULSE Pulsed Field Ablation System. intermittent) atrialfibrillation (AF) and is a unique new alternative to standard-of-care thermal ablation treatment. said Nick Spadea-Anello, president, Electrophysiology, Boston Scientific. "The
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillationAblation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. This is the most commonly used ablation catheter in the world for RF ablation and is fully integrated with the CARTO 3 System.
Rhythm control therapy and especially atrialfibrillation (AF) ablation are the focus of growing research in patients with AF. Recent findings suggest that reduction of AF burden mediates the beneficial effects of AF ablation on cardiovascular events and quality of life.
BackgroundCatheter ablation is frequently used to manage recurrent atrialfibrillation (AF) resistant to drug therapy, with pulmonary vein isolation (PVI) as a key tactic. The reconnection of pulmonary veins was discovered primarily in the anterior region of the right superior PV and the superior portion of the left superior PV.
Pulsed field ablation (PFA) has been demonstrated to be an effective strategy to treat paroxysmal atrialfibrillation (AF). This technology has recently been approved to treat paroxysmal AF in the United States (U.S). atrialfibrillationablation workflows rely heavily on 3D Electroanatomical Mapping (EAM).
Persistent atrialfibrillation (AF) ablation targeting extra-pulmonary vein drivers using various technologies has delivered varying results from no benefit to significant arrhythmia free survival.
Pulsed field ablation (PFA) is an emerging technology for atrialfibrillation (AF), but the serum metabolomic changes associated with PFA, particularly in the kynurenine pathway, remain poorly understood.
Catheter ablation (CA) is a cornerstone treatment for atrialfibrillation (AF). Pulsed field ablation (PFA) and very high-power short-duration (vHPSD) radiofrequency ablation are the most recent technologies for AF ablation.
Persistent atrialfibrillation (AF) remains a significant challenge and frequently requires substrate ablation. Because of its efficiency, Pulsed Field Ablation (PFA) has been used for persistent AF ablation. The Tailored AF trial showed that targeting areas of spatial temporal dispersion is more successful.
The application of pulsed field energy for atrialfibrillation (AF) has seen rapid advancements in recent years. The integration of 3D mapping technology, which allows detailed visualization of multielectrode ablation catheters and mapping of the left atrium and pulmonary veins, is anticipated to improve clinical outcomes.
Atrialfibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology.
Non-thermal pulsed field ablation (PFA) is an emerging technology to perform pulmonary vein isolation (PVI) for atrialfibrillation (AF). Different PFA systems are available, but no comparative outcome data exist.
Atrialfibrillation (AF) catheter ablation trials report arrhythmia-free survival using different post-ablation rhythm monitoring protocols, resulting in difficulties in the interpretation of the recurrence rates and comparison of ablation strategies and technologies.
Omnipolar technology near-field (OTNF) is an emerging cardiac mapping approach and may provide insights into electroanatomical substrate mapping during atrialfibrillation (AF) ablation.
Hemolysis is a recognized side effect of pulsed field ablation (PFA). Severe hemolysis can lead to acute kidney injury, potentially affecting morbidity of patients undergoing PFA for atrialfibrillation.
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment 5. Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for AtrialFibrillation Treatment 8.
Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technology innovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results.
FDA approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrialfibrillation and FDA 510(k) clearance for the new FARAVIEW Software, which will combine to provide visualization for cardiac ablation procedures with the FARAPULSE Pulsed Field Ablation System.
16, 2025 Primary results from the DEFINE AFib clinical study show the Medtronic LINQ family of insertable cardiac monitors (ICM), paired with a novel algorithm, were able to detect atrialfibrillation episodes and properly risk stratify patients as high risk prior to an AF-related healthcare utilization 80% of the time. 2024, May 15).
No data have been reported on cooling characteristics and the impact of variant pulmonary vein (PV) anatomy on atrialfibrillation (AF) recurrences after POLARx cryoballoon (CB) ablation.
Pulmonary vein (PV) isolation is the cornerstone of radiofrequency (RF) ablation for atrialfibrillation (AF). PV reconnection is the most common cause of recurrent AF following an ablation procedure.
Pulsed field ablation (PFA) and very-high power short-duration (vHPSD) radiofrequency ablation are the most recently introduced technologies for atrialfibrillation (AF) ablation. The procedural performance, safety, and effectiveness of PFA versus vHPSD are currently unknown.
Pulsed field ablation (PFA) is a safe and effective technology for catheter ablation of atrialfibrillation (AF). Multiple PFA-platforms for AF-ablation have been developed. However, evidence comparing the real-word implementation and performance of different PFA-systems is still limited.
Pulsed field ablation (PFA) for the treatment of paroxysmal atrialfibrillation (AF) was validated to be safe and effective.1 Widespread adoption of this potentially transformative technology has brought into the focus the economics of AF with new therapies requiring significant capital and disposable investment.
Pulsed field ablation (PFA) has recently been introduced as a novel routine ablationtechnology for paroxysmal atrialfibrillation (AF). It is also used as off-label therapy for persistent AF.
The 1st generation HeartLight laser balloon (LB) ablation is highly effective in achieving pulmonary vein isolation (PVI), and the safety and 12-month efficacy are comparable with paroxysmal atrialfibrillation (PAF) ablationtechnologies.
Pulsed field ablation (PFA) is a novel technology to perform ablation for atrialfibrillation (AF). Hemolysis and renal failure have been described after ablation with microsecond PFA.
As an energy source, pulsed field ablation (PFA) has generated tremendous excitement for AF treatment, largely due to its safety profile. All of the PFA technologies in clinical use, or being studied in clinical trials employ microsecond-scale pulses.
Non-thermal pulsed field ablation (PFA) is an novel technology to perform pulmonary vein isolation (PVI) for atrialfibrillation (AF). Different PFA systems are available, but no comparative data exist.
We have employed digital twin technology to perform extra pulmonary vein (PV) ablation in patients with non-paroxysmal atrialfibrillation (AF). We reported that high dominant frequency (DF) site ablation improved rhythm outcomes, but high maximal slope of action potential restitution curve (Smax) site ablation did not.
Pulsed field ablation (PFA) is a promising alternative to traditional catheter ablation for atrialfibrillation (AF). Dual-function PFA catheters, combining energy delivery and diagnostic capabilities, may improve procedure efficiency and outcomes.
Pulsed field ablation (PFA) is an emerging technology that delivers ultra-short bursts of ablative high electrical field energy. There are scarce systematic studies of the safety of atrialfibrillation (AF) ablation using PFA in real-world experience in the US.
The present invention relates to medical methods for transseptal access to the heart using steerable introducers based on the Company’s Morph DNA technology. This additional patent protection for BioCardia’s current and future products in this important existing market enhances shareholder value.
Pulsed field ablation (PFA) is an innovative technology recently adopted for treating atrialfibrillation (AF). Preclinical and clinical studies have reported a reassuring safety profile because of its tissue-specific effect, sparing adjacent tissues.1
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content